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Abstract
Increased mobilization of circulating endothelial progenitor cells may represent a new biological hallmark of
myeloproliferative neoplasms. We measured circulating endothelial colony forming cells (ECFCs) in 106 patients with
primary myelofibrosis, fibrotic stage, 49 with prefibrotic myelofibrosis, 59 with essential thrombocythemia or polycythemia
vera, and 43 normal controls. Levels of ECFC frequency for patient’s characteristics were estimated by using logistic
regression in univariate and multivariate setting. The sensitivity, specificity, likelihood ratios, and positive predictive value of
increased ECFC frequency were calculated for the significantly associated characteristics. Increased frequency of ECFCs
resulted independently associated with history of splanchnic vein thrombosis (adjusted odds ratio=6.61, 95% CI=2.54–
17.16), and a summary measure of non-active disease, i.e. hemoglobin of 13.8 g/dL or lower, white blood cells count of
7.8610
9/L or lower, and platelet count of 400610
9/L or lower (adjusted odds ratio=4.43, 95% CI=1.45–13.49) Thirteen
patients with splanchnic vein thrombosis non associated with myeloproliferative neoplasms were recruited as controls. We
excluded a causal role of splanchnic vein thrombosis in ECFCs increase, since no control had elevated ECFCs. We concluded
that increased frequency of ECFCs represents the biological hallmark of a non-active myeloproliferative neoplasm with high
risk of splanchnic vein thrombosis. The recognition of this disease category copes with the phenotypic mimicry of
myeloproliferative neoplasms. Due to inherent performance limitations of ECFCs assay, there is an urgent need to arrive to
an acceptable standardization of ECFC assessment.
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Introduction
The classical Philadelphia negative (Ph-neg) myeloproliferative
neoplasms, i.e. polycythemia vera, essential thrombocythemia, and
primary myelofibrosis, consist of clonal malignancies characterized
by the proliferation of one or more myeloid lineages that originate
at the level of stem cells. The discovery of recurrent molecular
abnormalities, like JAK2V617F and MPLW515L/K mutations [1],
has reinforced the Dameshek’s vision that these disorders have a
common pathogenetic mechanism and presumably belong to an
unique disease process [2]. The difficulties in dissecting the
continuum of clinical phenotypes are reflected in the recently
revised WHO classification [3], which arranges hematological,
morphological and molecular parameters to separate the three
clinical disorders. Even though this classification has endorsed the
concept of ‘‘prefibrotic-early stage of primary myelofibrosis’’, and
‘‘pre-polycythemic phase’’ of polycythemia vera to capture the
stepwise evolution of the diseases, the overlapping of clinical
phenotypes persists, and the category of ‘‘unclassifiable myelopro-
liferative neoplasms’’ continues to challenge the system [3]. Since a
precise classification predicts different natural history, prognosis,
and needs of therapy, to date, many studies have focused on
discovering new biological markers that could help unraveling the
phenotypic mimicry [4–8].
Recently, high mobilization of putative endothelial progenitor
cells has been proposed as a new biological hallmark of
myeloproliferative neoplasms. Colony forming unit-endothelial
or CD34-, CD133-, vascular endothelial growth factor receptor 2-
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selectively increased in the blood of patients with myelofibrosis,
specially in the early phase of the disease [9–11]. These findings
have originated the hypothesis that endothelial progenitor cell-
mediated neoangiogenesis could intervene in determining the
phenotypic profile of myeloproliferative neoplasms. However,
recent knowledge on the origin of endothelial progenitor cells have
weakened this interpretation. Functional and phenotypic overlap
between hematopoietic and endothelial progenitors have been
documented, while monocyte lineage has been proven able to
differentiate into endothelial cells in vitro [12,13].
Advancement in endothelial progenitor cell identification and
assessment has occurred in 2004 when Ingram et al. [14] described
a new category of cells, namely endothelial colony forming cells
(ECFCs), that isolated under precise culture conditions, are
organized in a hierarchy of precursor stages with different and
robust proliferative potential, and with vessel forming capacity in
vivo. Therefore, ECFCs are now considered a distinct colony type
originating from endothelial lineage [15].
In this paper we reconsider the clinical significance of
endothelial progenitor cells in classical Ph-neg myeloproliferative
neoplasms by applying the ECFC measurement to a large cohort
of patients. We compared the number of these cells in the different
categories of patients, and we tried to find correlations between the
cells numbers and disease’s characteristics.
Materials and Methods
Study overview
Since the ECFCs measurement suffers of the limitation that
only a very low number of colonies are detectable in humans, we
first designed a study that would adequately estimate within-
subject variability in ECFCs measurement. With this purpose,
thirty-one healthy volunteers (15 men and 16 women), and 29
subjects with myeloproliferative neoplasms were asked to be tested
in two different occasions, with a maximum of 5 days in between.
The main body of the study consists in a cross-sectional analysis
on 214 patients with classical Ph-neg myeloproliferative neo-
plasms. The study sample consisted of patients referred to the
Center for the Study of Myelofibrosis of the Fondazione IRCCS
Policlinico S. Matteo of Pavia, Italy, from March 2007 to March
2010.
Since during the study it became evident an association between
high frequency of circulating ECFCs and history of splanchnic
vein thrombosis, we collected samples from 13 additional patients
with splanchnic vein thrombosis in whom the diagnosis of
myeloproliferative neoplasm was thoroughly searched and exclud-
ed, with the aim of investigating the causal relationship between
splanchnic vein thrombosis and ECFCs mobilization. Samples
were obtained from patients referred to the Gastroenterology Unit
of the Maggiore Hospital Foundation of Milan or from Division of
Hematology of the Careggi Hospital of Florence.
The policies for collection and use of blood samples were
approved by the institutional review board of the IRCCS
Policlinico S. Matteo Foundation, and all patients gave written
consent for the donation of samples.
Study Cohorts
For the cross-sectional analysis, we selected patients for being at
diagnosis of disease or after diagnosis but without being receiving
any disease-modifying therapy. All patients had their initial
diagnosis re-evaluated by reviewing the diagnostic bone marrow
biopsy by an experienced pathologist (UM). Fifty nine patients
were diagnosed with polycythemia vera (n=38) or essential
thrombocythemia (n=21) according to the WHO criteria [3].
One hundred and six patients were diagnosed with primary
myelofibrosis according the WHO criteria for fibrotic myelofibro-
sis [3]. They also met the Italian Consensus Conference criteria for
myelofibrosis which requested a diffuse bone marrow fibrosis and
absence of bcr-abl translocation, plus a combination of morpho-
logic and clinical criteria [16]. Fifty five patients were categorized
under the term of prefibrotic myelofibrosis according with the
2001 WHO criteria [17] which impose absence or minimal
grade of reticulin fibrosis (EUMNET grading less than 1) [18],
in association with changes in bone marrow architecture,
granulopoiesis hyperplasia with predominance of immature and
segmented forms, and high number and clustering of atypical
megakaryocytes.
The normal control population consisted in 43 student or staff
members.
Clinical and Laboratory Assessment
At the time of blood withdrawn for measurement of ECFCs,
patients with myeloproliferative neoplasms were interviewed about
their medical history, focusing on previous thrombotic events. In
all patients, besides complete blood count and peripheral blood
smear for differential count, circulating CD34+ hematopoietic
progenitor cells were enumerated with standard method [5]. All
patients had the mutational status for JAK2 V617F determined
using the allele specific-PCR assay on DNA purified from
granulocytes, as reported [19]. A new bone marrow biopsy was
obtained in the majority of the patients with primary myelofibrosis
analyzed six months or later from the diagnosis.
The 13 control patients with splanchnic vein thrombosis were
investigated with bone marrow biopsy, JAK2 V617F and MPL
mutations [20], JAK2 exon 12 mutations [21], and clonality of
hematopoiesis with the method of HUMARA in female patients
[22], and myeloproliferative neoplasm was excluded.
The ECFCs assay method was that originally reported by
Ingram et al [14]. In brief, a median of 90610
6 mononuclear cells
(MNCs) (range 30–520) were plated on collagen-coated colture
dishes (BD Biosciences, San Jose `, CA, USA) in the presence of
endothelial cell growth medium EBM-2 MV Bullet Kit (Lonza),
and maintained at 37uC in 5% CO2 and humidified atmosphere.
Discard of non-adherent cells and first medium change were
performed after 2 days: thereafter medium was changed three
times a week. The number of ECFCs-derived colonies was scored
after 28 days by an inverted microscope. The outgrowth of
endothelial cells from adherent MNCs was characterized by the
formation of a cluster of cobblestone-appearing cells.
Statistical analysis
ECFCs were measured in frequency per 10
7 MNC. Within-
subject variance of ECFCs assay was calculated as the mean
square error from an analysis of variance model with ‘‘subject’’ as
main effect. We found that the frequency of ECFCs had a within
subject coefficient of variation of 1.2. From this measure, we
estimated that the number of subjects needed to detect difference
in group medians in an observation study was 43 per group [23].
The high coefficient of variation of ECFCs measurement
precluded an objective definition of an individual as having
increased level of ECFCs. However, we found that in repeated
measures of normal subjects, the frequency of ECFCs never was
greater than 0.59/10
7 MNCs. On the basis of this consideration
and for the purpose of this analysis, we used as operation definition
of increased frequency of ECFCs a value greater than the upper
level of normal.
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patients characteristics to identify the association between patients
with increased ECFCs frequency and age, sex, disease duration,
hemoglobin, white blood cell count, platelet count, number of
circulating CD34+ hematopoietic progenitor cells, serum lactate
dehydrogenase value, V617F mutational status of JAK2, diagnostic
category and prognostic score (International Working Group-
Myelofibrosis Research and Treatment, IWG-MRT [24]), at the
time of examination. The best cut-point of hematological markers
to identify individuals with increased ECFC frequency were
evaluated by constructing receiver-operating characteristics (ROC)
curves, which depicted the relationship between true positive
(sensitivity) and false positive (1-specificity) test results. For
predicting increased level of ECFCs we performed logistic
regression analysis in a univariate and multivariate setting that
included each characteristic and all interaction terms. We further
determined the sensitivity, specificity, positive predictive value,
positive likelihood value, and negative likelihood ratio for
increased frequency of ECFCs in predicting the markers that
were statistically significantly better performers.
Results were considered statistically significant when P values
were less than 0.05. All analyses were performed using
STATISTICA 9.0 software (Statsoft Inc, Tulsa, OK, USA).
Results
Table 1 describes the characteristics of study participants at the
time of ECFC sample collection by their initial diagnosis. We
limited the sample to patients who had no treatment effects.
Recruitment selection resulted in high prevalence of cases with
prefibrotic myelofibrosis, and in a population of patients with
primary myelofibrosis in fibrotic stage mostly in the low- or
intermediate 1- risk category according the IWG prognostic
classification. Prefibrotic myelofibrosis patients maintained low
IWG risk score in 82% of the cases, and absent or grade 1 bone
marrow fibrosis in 84%.
Table 1. Participant Characteristics, by Diagnostic Category.
Primary Myelofibrosis
(Fibrotic Stage) (n=106)
Prefibrotic Myelofibrosis
(n=49)
Polycythemia Vera or Essential
Thrombocythemia (n=59)*
Age, y, mean (range) 53.5 (21–83) 44.5 (22.72) 44.1 (17–86)
Male sex, male, n (%) 63 (59) 22 (40) 27 (45)
Time from diagnosis (months), mean (range) 57.1 (0–336) 60.3 (0–314) 36.2 (0–324)
Hemoglobin (g/dl), mean (range) 11.9 (5.1–18.3) 12.9 (8.8–16.7) 14.2 (11.1–18.1)
White blood cell count (610
9/L), mean (range) 11.6 (1.2–55) 7.8 (2.6–25.1) 10.9 (3.1–32.7)
Platelet count (610
9/L), mean (range) 368 (32–1186) 442 (22–909) 655 (110–1890)
Circulating CD34+ hematopoietic cells (610
6/L), mean
(range)
84.8 (0.3–1948) 14.9 (0.4–165) 5.8 (0.6–26)
Spleen index, cm
2, mean (range) 232 (90–1026) 151 (90–600) 114 (90–360)
Serum lactate dehydrogenase (units/L), mean (range) 903 (156–2588) 587 (214–1786) 365 (159–586)
JAK2 V617F mutational status, n (%):
wild type
heterozygous
homozygous
42 (40)
37 (35)
27 (25)
17 (35)
28 (57)
4( 8 )
14 (24)
30 (51)
15 (25)
IWG-MRT risk score, n (%):
low
intermediate-1
intermediate-2
high
74 (70)
16 (15)
12 (11)
4( 4 )
40 (82)
5( 1 0 )
4( 8 )
0( 0 )
NA
Bone marrow fibrosis, n (%)1:
grade 0
grade 1
grade 2
grade 3
0( 0 )
23 (32)
24 (33)
25 (35)
19 (62)
7( 2 2 )
3( 1 0 )
2( 6 )
NA
History of splanchnic vein thrombosis, n (%)
Portal or mesenteric vein thrombosis
Budd-Chiari syndrome
11 (10)
10 (9)
1( 1 )
20 (41)
16 (33)
4( 8 )
4 (7)
3 (5)
1 (2)
Mean time from SVT thrombosis to sample collection,
months, (range)
97.2 (2–288) 47.5 (4–168) 24.5 (0–60)
Patients in whom SVT was diagnosed at the time of
diagnosis of myeloproliferative neoplasm, n (%)
9 (82) 18 (90) 4 (100)
Patients with history of arterial thrombosis (stroke,
infarction, peripheral artery disease), n (%)
3( 3 ) 1( 2 ) 0( 0 )
Patients with history of deep vein thrombosis, n (%) 2 (2) 0 (0) 1 (2)
SVT=Splanchnic vein thrombosis.
*The group consisted in 38 patients with diagnosis of polycythemia vera and 21 patients with diagnosis of essential thrombocythemia.
1Bone marrow fibrosis was graded according EUMNET criteria
18 Bone marrow biopsy was evaluated at the time of ECFCs assay in 72 patients with a diagnosis of primary
myelofibrosis and 31 with a diagnosis of prefibrotic myelofibrosis.
doi:10.1371/journal.pone.0015277.t001
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age of 52 years (range 32–68). The median frequency of ECFCs
was 0.05/10
7 MNCs, with a range from 0 to 0.59/10
7 MNCs.
The frequency of ECFCs was not different between females and
males and there was no correlation between ECFCs frequency and
age.
Patients with prefibrotic myelofibrosis had the highest value of
ECFCs frequency (median=0.31/10
7 MNCs), which was signif-
icantly higher than normal subjects (P=0.04) and patients with
primary myelofibrosis or polycythemia vera/essential thrombo-
cythemia whose median value was 0 (P=0.001 and 0.03,
respectively).
Six patients (10%) with polycythemia vera or essential
thrombocythemia had elevated frequency of ECFCs (greater than
0.59/10
7 MNCs). No characteristic distinguished patients with
elevated ECFCs frequency from those with non-elevated frequen-
cy. Nineteen patients (18%) with primary myelofibrosis, fibrotic
stage, had elevated frequency of ECFCs, which was consistent
among female patients (odds ratio=3.09; 95% CI=1,09–8.78;
P=0.03), those aged less than 50 (odds ratio=3.25, 95%
CI=1.14–9.2, P=0.02), with a history of splanchnic vein
thrombosis (odds ratio=7.56; 95% CI=1.98–28.8; P=0.002).
Twenty-one patients (43%) with prefibrotic myelofibrosis had
elevated frequency of ECFCs which was consistent among those
with a history of splanchnic vein thrombosis (odds ratio=7.42;
95% CI=2.09–26.34; P=0.001).
By considering the whole cohort of patients with myeloprolif-
erative neoplasms, determination of the optimal cut-point to
identify elevated ECFCs for hemoglobin, white blood cell count
and platelet count yielded the following values: hemoglobin
13.7 g/dL or lower, white blood cell count 7.8610
9/L or lower,
platelet count 400610
9/L or lower (Table 2). We used the
interaction term of the three hematological parameters (hemoglo-
bin, white blood cell count, and platelet count), and we assigned
the name of ‘‘non-active disease’’ for those patients with the values
lower than the cut-points. Table 3 shows the results of univariate
and multivariate analysis. The association with elevated frequency
of ECFCs was modest in the patients who were females, younger
than 50 years, or with the diagnosis of prefibrotic myelofibrosis,
but was greater and highly statistically significant in patients who
had a non-active disease, and was greatest in those who had a
history of splanchnic vein thrombosis. At multivariate analysis the
history of spanchnic vein thrombosis and the phenotype of non-
active disease resulted independent predictors of increased ECFCs
frequency.
Table 4 shows the prediction ability of increased frequency of
ECFCs to identify the phenotype of non-active disease, and history
of splanchnic vein thrombosis. The greatest positive likelihood
ratio of increased ECFC was for history of splanchnic vein
thrombosis, that indicates that the odds of having a history of
splancnic vein thrombosis increased by 4.2 times if the test result
was positive as compared with a test negative. History of
splanchnic vein thrombosis had also the greatest predictive value
(44%).
To evaluate the biological effects of splanchnic vein thrombosis
on frequency of ECFCs, we studied 5 patients with Budd Chiari
syndrome and 8 with portal vein thrombosis without an
underlying myeloproliferative disease. They were 3 males (23%),
and their mean age was 52.8 years (range 36–67). The time from
diagnosis of splanchnic vein thrombosis to ECFCs assay ranged
from 0 to 96 months, mean 24 months, i.e. shorter than in patients
with prefibrotic myelofibrosis or fibrotic type primary myelofibro-
sis. Overall, 10 (77%) of patients had at least one thrombophilia
abnormality or one condition or disease known to predispose to
thrombosis. Five patients were taking oral contraceptives, and one
was on hormone replacement therapy. The median frequency of
ECFCs was significantly lower than in patients with myeloprolif-
erative neoplasm-associated splanchnic vein thrombosis of our
cohort (median, 0/10
7 MNCs vs. 1/10
7 MNCs; P=0.01), and no
patient had elevated ECFC frequency.
Discussion
Our analysis of a large cohort of patients with Ph-neg
myeloproliferative neoplasms shows that mobilization of endothe-
lial progenitor cells is consistently higher in patients who received a
diagnosis of prefibrotic myelofibrosis. However, the association
between elevated ECFCs frequency and the diagnosis of
prefibrotic myelofibrosis did not persist after adjustment for the
contribution of the other potential influential factors, like age less
than 50 years, female sex, a phenotype of non-active disease, and
history of splanchnic vein thrombosis. As a matter of fact, the
phenotype of non-active disease, and history of splanchnic vein
thrombosis resulted independently associated with high frequency
of circulating ECFCs at multivariate analysis. The definition of
active and non-active disease originated by this data set assumes
absence of active myeloproliferation. A patient with non-active
Table 2. Results of Univariate and Multivariate Analysis of Disease Characteristics Associated with Increased Frequency of ECFCs.
Variable
Patients,
n/n
Patients with Variable
when Increased ECFCs
Frequency is Present, n Univariate analysis
Multivariate
analysis
Unadjusted Odds Ratio
for Increased ECFCs
Frequency (95% CI)
P value Adjusted Odds Ratio
for Increased ECFCs
Frequency (95% CI)
P value
Female sex 102/214 29 2.24 (1.09–4.69) 0.026
Age lower than 50 years 99/214 17 2.72 (1.28–5.68) 0.008
Diagnosis of prefibrotic
myelofibrosis
56/214 21 2.84 (1.36–5.81) 0.005
Phenotype of non-active
disease
27/214 13 4.67 (1.81–11.94) 0.001 4.43 (1.45–13.49) 0.008
History of splanchnic vein
thrombosis
35/214 20 7.63 (3.34–17.91) ,0.001 6.61 (2.54–17.16) ,0.001
ECFCs=Endothelial colony forming cells.
doi:10.1371/journal.pone.0015277.t002
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13.7 g/dL), leukocyte count (less than 7.8610
9/L), and platelet
count (less than 400610
9/L). This definition is thus based on fewer
and simpler parameters than those defining the low-risk category
of patients with primary myelofibrosis according to the IWG-
MRT criteria that allow higher number of white blood cells
(25610
9/L) and no cut-off for platelet count.
Despite the significant association of increased ECFCs frequen-
cy with history of splanchnic vein thrombosis and the phenotype of
non-active disease, the ability to use ECFCs elevation as a
biomarker for the prediction of these characteristics was moderate,
being the predictive value 44.4% and 28.2%, respectively. This
could be justified by the relatively low prevalence of history of
splanchnic vein thrombosis and non-active phenotype in our
cohort, considering that the predictive ability of any biomarker
depends on the prevalence of the predicted event in that
population. So, in populations with a larger proportion of cases
with splanchnic vein thrombosis and non-active disease, higher
predictive ability is expected. Furthermore, the 1.2 coefficient of
variation of ECFCs assay we have determined in the preliminary
analysis of this study, implies a high proportion of false-negative
and false-positive patients in the ascertainment of high mobilizers.
The association between splanchnic vein thrombosis and
elevated frequency of ECFCs generates the question whether the
thrombotic episode per se mobilizes ECFCs. For this question, we
intentionally selected a cohort of patients with splanchnic vein
thrombosis non associated with a myeloproliferative neoplasm. We
documented that the association between increased ECFCs
frequency and splanchnic vein thrombosis was lacking. So, with
inductive reasoning we concluded that the association depends on
the underlying myeloproliferative neoplasm that predisposes
patients both to develop thrombosis and to mobilize ECFCs. This
result suggests several important future directions for research
addressing the role of ECFCs on the splanchnic thrombotic event.
In the interpretation of the results of this study we set off the
biological strength and the clinical relevance of the correspon-
dence between high ECFCs frequency and non-active phenotype
and high risk of splanchnic vein thrombosis, respectively.
Accordingly, we interpreted high mobilization of ECFCs in the
realm of myeloproliferative neoplasms as the biological hallmark
of a separate category of patients, more than of a phase in the
evolution of the myeloproliferative process. This is also supported
by the fact that high ECFCs mobilizers were mostly females and
had preferentially young age.
The idea that patients with non-active phenotype and high-risk
of splanchnic vein thrombosis would identify a separate category
of patients is not fully original. Indeed, patients we have identified
through the measurement of mobilized endothelial progenitor cells
are similar to those we singled out by pattern recognition in 1991
and we defined with the name of ‘‘atypical myeloproliferative
disorder with high thrombotic risk and slow disease progression’’
[25]. Moreover, the patients’ characteristics identified in this work
convincingly accommodate the series of cases with an occult or
latent myeloproliferative disorder associated with splanchnic vein
Table 3. Ability to Predict the History of Splanchnic Vein Thrombosis, and the Phenotype of Non-Active Disease by Increased
Frequency of ECFCs.
Marker
Sensitivity
(95% CI), %
Specificity
(95% CI)%
Positive LR
(95% CI)
Negative LR
(95% CI)
Positive Predictive
Value,%
History of
splanchnic vein
thrombosis, n
No history of
splanchnic vein
thrombosis, n
ECFCs.0.59/
10
7 MNCs
20 25 57.1 (40.0–73.7) 86.4 (80.6–91.0) 4.2 (2.6–6.7) 0.5 (0.3–0.7) 44.4 (29.6–60.0)
ECFCs,0.59/
10
7 MNCs
15 159
Phenotype
of non-active
disease
Phenotype of
active disease
ECFCs.0.59/
10
7 MNCs
13 33 48.1 (28.7–68.0) 80.8 (74.1–86.4) 2.5 (1.5–4.1) 0.6 (0.4–0.9) 28.2 (16.0–43.4)
ECFCs,0.59/
10
7 MNCs
14 139
LR=likelihood ratio.
doi:10.1371/journal.pone.0015277.t003
Table 4. Sensitivity, Specificity, and Cut-off Value for the Ability of Hematological Parameters to Identify Patients with Increased
Frequency of ECFCs.
Parameter Sensitivity % Specificity % Cut-off value AUC (95% CI) P level
Hemoglobin, g/dL 85 36 #13.8 0.59 (0.52–0.66) 0.037
White blood cell count, 10
9/L 70 61 #7.8 0.67 (0.61–0.74) ,0.001
Platelet count, 10
9/L 66 53 #400 0.57 (0.49–0.64) 0.045
AUC=Area under the curve.
doi:10.1371/journal.pone.0015277.t004
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myeloproliferative process is associated with the thrombotic event
[26–30].
The major limit of our experimental approach is that the
appreciation of high endothelial progenitor cell frequency was
obtained with an assay that has inherent performance limitations
due to low analytical read out, repeatability, and practicality.
Thus, the importance of this study relies on the appreciation that a
biomarker is able to identify a separate category of myeloprolif-
erative neoplasm. However, there is an urgent need to arrive
either to an acceptable standardization of ECFCs assessment, or to
find more feasible, highly correlated, biomarkers that would be
clinically included in the work-up of early stages, indolent or
unclassifiable myeloproliferative neoplasms. The recognition of
such a category of patients can help in unraveling the phenotypic
mimicry of myeloproliferative neoplasms and in a more homog-
enous case reporting in clinical studies. Moreover, since splanchnic
vein thrombosis may occur without the signs of an underlying
myeloproliferative neoplasm, having a new diagnostic biomarker
could help health care professionals be more successful in bringing
about the diagnosis of the associated myeloproliferative neoplasm.
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